Psychomotor Retardation in Bipolar Disorder

Tired, stressed businesswoman at laptop with head in hands

Caiaimage / Rafal Rodzoch / Getty Images

In This Article
Table of Contents

Experiencing psychomotor retardation feels as if a dial has been turned to put you on slow speed. The resulting effects include sluggish or diminished body movements, usually accompanied by a similar slowing of your thought processes. The physical manifestations vary in scope and severity but are usually obvious to both loved ones and healthcare professionals.

Psychomotor retardation occurs commonly during depressive episodes of bipolar disorder as well as major depressive disorder. In these circumstances, the effects are usually temporary and recede as the depression lifts.

The development of psychomotor retardation does not always signal a depressive episode. Other situations and conditions—such as drug side effects and certain medical diseases—can also trigger reduced or slow physical and mental activity. 

Signs and Symptoms

People with psychomotor retardation move, speak, react, and usually think more slowly than normal. This can manifest in a variety of ways, largely depending on the severity of the impairment.

An affected person's speech is noticeably slow and may be punctuated by long pauses or losing the train of thought.

Delayed responsiveness and difficulty following another person's conversation are also common. Complex mental processes—such as calculating a tip or mapping out directions—take longer to accomplish. Common examples of physical manifestations of psychomotor retardation include: 

  • Being sluggishness when walking or changing positions, such as getting up from a chair
  • Having an impaired ability to perform tasks requiring eye-hand coordination, such as catching a ball, shaving, and applying makeup
  • Reacting to situations slowly, such as when reaching for a falling object
  • Showing diminished facility with fine motor tasks, such as writing, using scissors, and tying shoelaces 
  • Slumping when standing and having poor posture
  • Speaking in a soft, monotonous voice
  • Staring into space and having reduced eye contact

A person with severe psychomotor retardation may appear catatonic. In this state, the person does not respond normally to others or the environment. Catatonia represents a medical emergency, as it can become life-threatening.

Causes

Several disorders and conditions can cause slowed mental and physical activity. This occurs most frequently in people experiencing a depressive episode due to major depression or bipolar disorder.

The degree of physical and mental blunting often correlates to the severity of the depressive episode. Other psychiatric disorders sometimes associated with psychomotor retardation include:

Nervous systems diseases and other conditions that might cause blunted or slow physical and mental activity include:

  • Certain genetic conditions, such as Huntington's disease
  • Dementia
  • Hypothyroidism
  • Medication side effects, especially psychiatric medicines 
  • Parkinson's disease and related conditions

Treating Psychomotor Retardation

Reviewing current medications is one of the first steps in addressing psychomotor retardation. This is important to determine whether medication side effects might be triggering the physical and mental slowness. Certain anti-anxiety and antipsychotic medications commonly prescribed for bipolar disorder are possible culprits.

If other causes have been ruled out, medication is typically the first line of treatment for people experiencing psychomotor retardation associated with a depressive episode.

The choice of medication or a combination of medicines is made on an individual basis. Current and past medications and an individual's response to them are important considerations in drug treatment decisions.

Common medication options for people with bipolar disorder experiencing a depressive episode include Abilify (aripiprazone), Depakote (valproic acid), Lamictal (lamotrigine), Latuda (lurasidone), lithium, Seroquel (quetiapine), and Zyprexa (olanzapine), among others.  

With severe depression, especially if accompanied by catatonia, loss of touch with reality, or a high risk of suicide, electroconvulsive therapy (ECT) may be an option. While it is one of the fastest and most effective ways to treat bipolar depression, ECT is generally undertaken only if other treatment options fail.

Once the right combination of medications is found, psychotherapy and other non-medical therapies may be used in addition to medication to support long-term mood stabilization.

If you are having suicidal thoughts, contact the National Suicide Prevention Lifeline at 1-800-273-8255 for support and assistance from a trained counselor. If you or a loved one are in immediate danger, call 911.

For more mental health resources, see our National Helpline Database.

Was this page helpful?
Article Sources
Verywell Mind uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Bennabi D, Vandel P, Papaxanthis C, Pozzo T, Haffen E. Psychomotor Retardation in Depression: A Systematic Review of Diagnostic, Pathophysiologic, and Therapeutic ImplicationsBiomed Res Int. 2013;2013:158746. doi:10.1155/2013/158746

  2. Pier MP, Hulstijn W, Sabbe BG. Psychomotor retardation in elderly depressed patients. J Affect Disord. 2004;81(1):73-77. doi:10.1016/j.jad.2003.08.002

  3. Primo de Carvalho Alves L, Sica da Rocha N. Lower levels of brain-derived neurotrophic factor are associated with melancholic psychomotor retardation among depressed inpatients. Bipolar Disord. 2018;20(8):746-752. doi:10.1111/bdi.12636

  4. Pereira J, Bruera E. Depression With Psychomotor Retardation: Diagnostic Challenges and the Use of Psychostimulants. J Palliat Med. 2001;4(1):15-21. doi:10.1089/109662101300051906

  5. Buyukdura JS, McClintock SM, Croarkin PE. Psychomotor retardation in depression: Biological underpinnings, measurement, and treatmentProg Neuropsychopharmacol Biol Psychiatry. 2011;35(2):395-409. doi:10.1016/j.pnpbp.2010.10.019

Additional Reading